<code id='D8846838CD'></code><style id='D8846838CD'></style>
    • <acronym id='D8846838CD'></acronym>
      <center id='D8846838CD'><center id='D8846838CD'><tfoot id='D8846838CD'></tfoot></center><abbr id='D8846838CD'><dir id='D8846838CD'><tfoot id='D8846838CD'></tfoot><noframes id='D8846838CD'>

    • <optgroup id='D8846838CD'><strike id='D8846838CD'><sup id='D8846838CD'></sup></strike><code id='D8846838CD'></code></optgroup>
        1. <b id='D8846838CD'><label id='D8846838CD'><select id='D8846838CD'><dt id='D8846838CD'><span id='D8846838CD'></span></dt></select></label></b><u id='D8846838CD'></u>
          <i id='D8846838CD'><strike id='D8846838CD'><tt id='D8846838CD'><pre id='D8846838CD'></pre></tt></strike></i>

          Home / fashion / explore

          explore


          explore

          author:knowledge    Page View:871
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In